I'm starting this thread to collect what has been heard or confirmed for those of us trying to have better understanding.
Here is what I know: some managers will be let go and districts will be bigger, metropolitan areas with 4+ reps will see some cuts, only full districts really need to worry. Change will likely happen soon hence the reason we have no samples and our sample audits are happening now. Vesneo isn't coming until at least April of next year and it will probably result in hiring. If you are displaced you may have a place in another division of Valeant until the Vesneo launch then you may have the opportunity to go back to eye care.
Rumors: Prolensa and Lotemax will be put together. Makes sense, mirrors Alcon, they are now established products so no need for two teams. Whoever is the new Prolensa/Lotemax rep will easily be able to roll out sub-micron loteprednol. Back in the day when it was just B & L and ISTA was a separate company there was a team of anti-infective reps, they had huge territories. There will probably be a team similar to that which will also cover glaucoma. Then once Vesneo is launched they will likely split those territories into smaller ones and hire more people. It makes sense. So what does that mean for you? Since they will likely be combining Prolensa with Lotemax that would cut the sales force into half. Of the leftover reps, most likely some of them will be the new anti-infective/glaucoma reps with huge territories, leading to some cuts of whoever is left over. This will likely be 10-15% cuts. Everyone's territories will probably look different and you will have different products but most will be safe. Just one per metropolitan area really needs to worry. Again all rumor! I'm not a manager just trying to help those seeking answers.
Here is what I know: some managers will be let go and districts will be bigger, metropolitan areas with 4+ reps will see some cuts, only full districts really need to worry. Change will likely happen soon hence the reason we have no samples and our sample audits are happening now. Vesneo isn't coming until at least April of next year and it will probably result in hiring. If you are displaced you may have a place in another division of Valeant until the Vesneo launch then you may have the opportunity to go back to eye care.
Rumors: Prolensa and Lotemax will be put together. Makes sense, mirrors Alcon, they are now established products so no need for two teams. Whoever is the new Prolensa/Lotemax rep will easily be able to roll out sub-micron loteprednol. Back in the day when it was just B & L and ISTA was a separate company there was a team of anti-infective reps, they had huge territories. There will probably be a team similar to that which will also cover glaucoma. Then once Vesneo is launched they will likely split those territories into smaller ones and hire more people. It makes sense. So what does that mean for you? Since they will likely be combining Prolensa with Lotemax that would cut the sales force into half. Of the leftover reps, most likely some of them will be the new anti-infective/glaucoma reps with huge territories, leading to some cuts of whoever is left over. This will likely be 10-15% cuts. Everyone's territories will probably look different and you will have different products but most will be safe. Just one per metropolitan area really needs to worry. Again all rumor! I'm not a manager just trying to help those seeking answers.